Tabrecta tablets 200mg, containing Capmatinib hydrochloride hydrate, are manufactured by Novartis Pharma. This medication (YJ code: 4291067F2020, 200mg x 1 tablet) is a kinase inhibitor primarily used for adult patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations.
Tabrecta tablets 200mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →